The objective was to evaluate the ef®cacy and safety of topically applied cream containing testosterone, isosorbide dinitrate and co-dergocrine mesylate compared to testosterone cream in the treatment of erectile dysfunction in aged men with low sexual interest. A randomised doubleblind crossover trial was performed over two months. The subjects were 42 men with erectile dysfunction and low normal or slightly depressed testosterone level randomly allocated to two equal groups. Polypharmacy cream containing testosterone 0.8%, isosorbide dinitrate 0.5% and co-dergocrine mesylate 0.06% was applied for one month, and testosterone 0.8% cream for another month. The serum level of total testosterone was measured before and after each phase of treatment. Response to each therapy was assessed by a sexual questionnaire, measurement of tumescence and repeat penile duplex ultrasonography. Twenty-eight patients reported full erection and satisfactory intercourse with the polypharmacy cream. Thirteen men reported full erection and satisfactory intercourse with either cream. Polypharmacy cream increased penile arterial¯ow (P`0.001) and induced tumescence in 34 patients in lab. No patient in either phase of the study has tumescence or a signi®cant increase in cavernous arterial peak systolic velocities after the application of testosterone cream. Serum level of total testosterone increased in all patients (P`0.05). Sexual desire was improved in 85% and 62% of patients during the treatment with polypharmacy cream and testosterone cream, respectively. No marked side effects were reported after either of them. Topical treatment with cream containing testosterone and vasoactive agents may represent a new effective treatment for erectile dysfunction associating with aging.
Introduction
Sexual function declines with age even in healthy men, it was thought that as many as 52% of men more than 40 y of age have some degree of sexual dif®culty. 1 It has also become clear that levels of testosterone decrease slowly in men after the age of 40 y 2 The fall is greater in the free fraction of testosterone because of the rise in the sex hormone binding globulin. 3 The causal relationship has not been established between hypogonadism and erectile dysfunction. 4, 5 Also, the minimum level of testosterone needed to maintain the sexual function has not been established. 6 Although there is no ®rm evidence that testosterone supplementation results in enhancement of erectile function, 5 the National Institute of Health (NIH) consensus development panel on impotence proposed that for some patients with hypogonadism, androgen replacement therapy may sometimes be effective in improving erectile function. 7 Penile erection is a complex psycho-neurovascular phenomenon and the cause of impotence can be multifactorial, a large number of impotent men after the age 40 y have been found to have a low normal or low androgen levels in addition to organic anda or psychogenic cause. 6, 8, 9 This explains why the individual merits of the use of androgen supplement as a sole treatment remain controversial.
Combination therapy may be an attractive option in the treatment of erectile dysfunction associated with aging. Based on an extensive medical literature review, the American Urological Association (AUA) recommended the use of vasoactive drugs (i.c.) as one of the effective treatment options for organic impotence. 10 We have previously reported a high success rate in the treatment of psychogenic impotence and moderate success rate in the treatment of organic impotence by a topically applied mixture of vasoactive agents. 11 Our current work is designed to assess the effect of a topically applied mixture of vasoactive drug plus testosterone in impotent patients with low normal or mild hypogonadism associating with aging and compare the results to those obtained after the use of testosterone alone.
Because the long acting testosterone esters injection result in a widely¯uctuating serum concentration from peak values above the normal range one day after an injection to a nadir at or below the lower limit of normal for few days before the next injection and to avoid the`®rst pass' effect and hepatotoxicity of oral preparations and to avoid the skin irritation of transdermal patch, we compounded testosterone in the form of a cream for a daily topical use. 12 
Subjects and methods
A total of 42 patients 41 to 67-y-old (mean 54 y) with erectile dysfunction of 4 ± 72 months duration participated in this study. Subjects were considered candidates for this study when they had a decrease in libido and serum total testosterone level near the lower end of the normal adult range or slightly depressed than normal range. Although the normal range is greater than 250 ngadl, patients were accepted for the study when the level was between 200 and 350 ngadl. This was to compensate for the higher sex hormone-binding globulin level in older men. Those patients were described by Carani et al 13 as having a mild hypogonadism.
Patients previously treated with any androgen preparation or intracavernous vasodilators had a wash out period of no less than 6 weeks. Patients were excluded if they had history of prostatic diseases (prostatic cancer, recurrent prostatitis, benign hyperplasia or prostatic hypertrophy), cavernous ®brosis, primary hypogonadism, anatomical deformation of the penis, glaucoma, hypotension or cardiac arrhythmia. No patient was a smoker at the time of study. A physical examination and laboratory evaluation including blood count, serum chemistry studies PSA (prostatic speci®c antigen), testosterone and prolaction determinations, penile duplex ultrasound scanning and a papaverine test were performed.
Two weeks after the papaverine test each patient was asked to determine which of the two different treatments was the more useful. One cream contained a combination of co-dergocrine mesylate 0.06%, isosorbide dinitrate 0.5% and testosterone 0.8%, and the other cream contained only testosterone 0.8%. The two creams were prepared by ESPICO (Giza, Egypt). Patients attended the neurology outpatients clinic at the hospital and gave their informed consent to participate in the study. Investigators were blind to which cream was being used by means of coded labels. The two preparations looked similar and had identical packaging. Each patient was given 15 divided doses of 2 g of cream (on the basis of one dose daily).
After ®fteen days, each patient attended the clinic for investigation and was given another 15 divided doses of 2 g of cream.
The patients were randomly assigned to two groups of 21 subjects each. Phase I of the study lasted one month. Group 1 was given the polypharmacy cream applied once daily on the penile shaft and glans before bed time, if intercourse was going to take place then the cream was applied on the penile shaft and glans 15 min before intercourse. Patients were informed that erotic stimulation was necessary before intercourse. Group 2 was given testosterone cream applied in the same way as the polypharmacy cream. At the end of phase I all patients stated that they were compliant with taking the medication as prescribed. After a washing period of one week the complete crossover design of the study was implemented in phase II, Group 1 and 2 switched the cream used for an additional month.
The effect of the two creams on the penile size and arterial¯ow were measured in the laboratory before and after each phase of trial. No erotic stimulation was used during these laboratory measurements. These parameters were measured after 5, 10, 15, 30 and 60 min after application of 2 g of cream on the penile shaft and glans. Patients reported daily their experience on questionnaires returned by the patients every 15 days during the study. The questionnaire investigated four main areas: sexual interest and activity, erectile response, patient's satisfaction and side effects. The questionnaire include two questions designed to assess separately sexual interest and activity: (1) How often did you think about sex in the last 24 hours? (frequency); and (2) How much did this excite you? (excitement). Answers were recorded by the patients on separate visual analogue semantic scales. 14, 15 Erectile response and patient's satisfaction were measured on semantic scales. 16 Erectile response was graded as full erection which implies successful intercourse; partial erection, in which penetration but not intercourse is possible; tumescence, in which penetration is not possible; and no response. The best response during each phase of trial was used in the statistical analysis if it had been repeated at least twice during each phase.
Statistical analysis included Student's t-test (peak ow velocity; serum levels) and w 2 test (erectile response, sexual desire) for comparison of the two groups (unpaired data) and it includes paired t-test (peak¯ow velocity, serum levels) and McNemar's test (erectile response and sexual desire) for analysis 
Results
Duplex ultrasound scanning results obtained before and after each phase of study are shown in Table 1 . Application of testosterone cream did not signi®cantly increase cavernous arterial systolic peak ow velocity in all patients. No patient in either group before and after treatment had a post-application of testosterone cream cavernous arterial systolic peak¯ow velocity greater than 0.11 cmas.
As expected, polypharmacy cream was highly effective in increasing penile arterial¯ow (P`0.001). Also, the systolic peak¯ow velocities means demonstrated statistically signi®cant differences (P`0.001) between the effect of polypharmacy cream and testosterone cream throughout the study. There were differences between the effects of polypharmacy cream on penile arterial¯ow obtained before starting the treatment with polypharmacy cream and after treatment. These differences were statistically signi®cant only in group 1 (P`0.05).
Objective monitoring of tumescence did not show any signi®cant change after application of testosterone cream before or after any phase of treatment. However, polypharmacy cream was effective in inducing complete tumescence in 7 patients and partial tumescence in 20 patients when it was tested before starting the treatment. After 30 days of daily use of polypharmacy cream, it caused tumescence in 34 patients, the tumescence being complete in 11 and partial in 23. Tumescence was not achieved in eight patients.
Testosterone levels
Morning serum testosterone levels were measured before and after each phase of treatment (12 h after the last dose). Serum testosterone responses to creams were similar ( Table 2 ). After 30 days total testosterone levels were slightly elevated but signi®cantly (P`0.05) in response to polypharmacy cream or testosterone cream and were all within the middle of the normal range. However, no differences in mean total testosterone levels were noted in the two groups.
Subjective assessment of sexual function
A w 2 analysis of the patients' response when they were asked whether cream A (polypharmacy cream) or cream B (testosterone cream) was more active, revealed that subjects were able to con®rm the high valuable effects of the polypharmacy cream.
Overall sexual function as re¯ected by the total questionnaire score including sexual desire (libido), frequency of sexual activity, penile responses and satisfaction was signi®cantly increased during the polypharmacy cream therapy compared to the testosterone cream therapy (P`0.001).
Visual analogue scale diaries documented positive changes in the levels of frequency and excitement of sexual thoughts in 85% and 62% of patients during treatment with polypharmacy cream and testosterone cream, respectively.
A complete response (full erection and sexual interest) was reported by 28 of 42 patients (67%) and a sexual interest with or without partial improvement of erection was reported by eight patients (19%) after treatment with polypharmacy cream. 
Topically applied vasoactive agents A Gomaa et al
After treatment with testosterone cream, a complete response was reported by 13 patients (31%). Sexual interest with or without partial improvement of erection was also reported by another 13 patients (Table 3) . There was no marked differences between the penile responses after treatment with polypharmacy cream in phases I and II. However, there was a signi®cant difference between the penile responses in phase I and phase II after testosterone cream (P 0.059). The number of patients with complete response after testosterone cream in phase II (43%) (who received polypharmacy cream in phase I) was signi®cantly higher than those in phase I (14%) (who received testosterone cream before polypharmacy cream). This is evidence of a sequence effect due to the previous treatment with polypharmacy cream.
When the mean number AE s.d. of full erection with satisfactory intercourse per month for patients with complete response (derived from questionnaire results) was evaluated, a signi®cant amelioration (P`0.05) was noted during the polypharmacy cream therapy (6.46 AE 2.7) compared to testosterone therapy (4.05 AE 1.8).
Side effects of the medications were minimal. Two patients in phase I and three in phase II initially experienced mild and transient headaches on the polypharmacy cream therapy. There were no signi®cant changes in pulse rate, blood pressure or laboratory safety data. No signi®cant increase of PSA was recorded, serum PSA levels at base line were 2.1 AE 0.3 ngaml for all patients; serum PSA levels after 2 months of treatment with polypharmacy cream and testosterone cream were 2.4 AE 0.5 ngaml.
Discussion
Impotence is strongly associated with aging. 1 Although a causal relationship has not been established between the mild hypogonadism and erectile dysfunction in aged males, 17 many physicians have treated patients with low normal or slightly depressed testosterone levels with exogenous testosterone and have seen a positive response. 5,9,18 ± 23 In the present study, testosterone cream signi®-cantly increased the serum testosterone levels in all patients but a complete sexual response was observed in only 31% of patients (most of them in phase II) and improvement of sexual interest (libido) in 62% of patients. The effects of androgens on libido and sexual behaviour is well established, 21 ± 23 but their effect on the erectile mechanism remains contraversal. 1, 4, 5, 14 However, Aydin et al 20 reported that response to exogenous testosterone may be mediated by heightened libido, as well as the known antidepressant effect of androgens. These effects may contribute to the return of potency in patients with stational or psychogenic impotence and in patients with underlying endocrine abnormalities. Also Arvert et al 23 suggested that the primary effect of androgen in male sexuality is on libido and centrally controlled erection. Our ®ndings are in agreement with these authors since the improvement in erectile response after testosterone cream has been shown in patients with psychogenic impotence particularly in phase II who were previously treated with polypharmacy cream (sequence effect).
Combination of testosterone and vasoactive agents
Although certain patients may respond to hormonal augmentation, the clear message from the low success rate with testosterone cream treatment seems to be that sexual dysfunction in aged males cannot be treated successfully with testosterone as a sole agent. This ®nding may be explained by the report of Feldman et al 1 who concluded that the erectile dysfunction in aged males has multiple determinants including vascular, psychogenic Topically applied vasoactive agents A Gomaa et al causes and modi®able para-aging phenomena. In addition, it has become clear that penile erection is a complex neurovascular phenomenon involving coordinated hemodynamic event and interaction of nerves, androgen, neurotransmitters and smooth muscle. 24, 25 Polypharmacy cream contains two agents absorbed through the skin and is an attractive way to treat erectile dysfunction. 11 Isosorbide dinitrate generates nitric oxide either spontaneously or after metabolism in smooth muscle. Nitric oxide activates the guanylate cyclase enzyme leading to the formation of cyclic GMP causing relaxation of smooth mucle. 26, 28 Co-dergocrine mesylate blockade the alpha adrenergic receptors within the corpora cavernosa causing dilation of arteries and arterioles. It also has central dopaminergic action which enhances the central arousability to sexual stimulation. 29, 30 The two agents will work together to increase the ®lling of corpora with blood and restrict venous out¯ow. This combination will not produce erection in the absence of a drive on physiological mechanisms of erection because its main action is through the potentiation of the released neurotransmitters during sexual stimulation.
The addition of this combination to testosterone, in this study, signi®cantly enhanced the objective and subjective parameters of sexual function. Objective penile hemodynamic parameters in our study were signi®cantly improved after polypharmacy cream but not after testosterone cream as documented by marked increase of cavernous arterial systolic peak¯ow velocities and induction of tumescence in 81% of patients after polypharmacy cream.
Duplex ultrasonography is an objective measure of penile response to therapy. 31, 32 It indicates that testosterone has no direct effect on penile hemodynamic parameters. Supporting our observation, Arver et al 23 suggested that testosterone may have only a facilitating role in erectile function and may accomplish this role by modulating the expression of nitric oxide synthetase in corpus cavernosum tissue, thus increasing production of nitric oxide, a key regulator in erectile function. However, the recent animal data suggested that penile erection is completely dependent on androgens, presumably because of their role in the maintaince of penile NOS activity. 33, 34 Shabseigh 35 reported that the experimental animal observations showed that androgens support erectile function through a direct effect on the erectile tissue.
Mechanism of the combination
Based on patient subjective assessments, overall sexual function particularly the penile response was signi®cantly higher during polypharmacy cream use than during testosterone cream use. The percentage of patients with full erection showed striking improvement from 31% during testosterone cream to 64% during polypharmacy cream treatment. This improvement of erectile response may due to the combination of the reported effect of testosterone on nitric oxide synthetase 33, 35 and action of nitric oxide generated from isosorbide dinitrate. Testosterone may also enhance responsiveness of cavernosal smooth muscle to co-dergocrine mesylate. Reilly et al 36 presented evidence suggesting that one mechanism by which androgens maintain erectile function is by regulating the alpha-1-adrenergic responsiveness of cavernosal smooth muscle. Recently, it has been demonstrated that long lasting additional testosterone increased the relaxant response of corpus cavernosum to vasoactive agent (ADP), 37 though, testosterone in our preparation enhanced the vasoactive effect of isosorbide dinitrate. Moreover, the dopaminergic effect of codergocrine mesylate may magnify the central action of testosterone.
We conclude that erectile dysfunction associated with aging may have multiple causes, combination of testosterone with vasoactive agents (isosorbide dinitrate, co-dergocrine mesylate) may have the capability to manage the multiple factors causing erectile dysfunction in aged males. It is a well tolerated and effective non-invasive therapy for male erectile dysfunction with low sexual interest or with low normal testosterone levels.
Editorial Comment
This paper reports results of topical application of testosterone, disorbide nitrate and co-dergocrine mesylate compared to testosterone alone in 42 men with erectile dysfunction associated with decreased libido and border line levels of testosterone. The design was crossover. The methodology used for this study is somewhat questionable. First of all there is no placebo group or arm. A`complete sexual response' is reported in 31% of patients receiving testosterone alone which is, in this kind of population, similar to the usual placebo response rate. The questionnnaire used for the evaluation of libido, frequency of sexual activity, penile responses and satisfaction is not described and not validated. Accordingly the present results need to be considered with a lot of caution. They are too preliminary to draw any conclusion except that such local treatment must be studied in a multicenter controlled study vs placebo.
In general, I would like to strongly recommend the evaluation of any new therapeutical modalities according to the well de®ned criteria of clinical research. 1 This represents the only condition for the therapeutical area of sexual dysfunction to reach the level of credibility. Otherwise we will stay with anecdotal reports resulting from uncontrolled studies and the ®eld of sexual medicine will be at risk of staying outside scienti®c and evidence-based medicine.
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